1 Repeated population-based surveys of antibodies against SARS- 2 CoV-2 in Southern Brazil

3
4 Mariângela F Silveira, Aluísio J D Barros, Bernardo L Horta, Lúcia C Pellanda, Odir A
5 Dellagostin, Claudio J Struchiner, Marcelo N Burattini, Andréia R M Valim, Evelise M
6 Berlezi, Jeovany M Mesa, Maria Letícia R Ikeda, Marília A Mesenburg, Marina
7 Mantesso, Marinel M Dall'Agnol, Raqueli A Bittencourt, Fernando P Hartwig, Ana M B
8 Menezes, Fernando C Barros, Pedro C Hallal*[#], Cesar G Victora[#]

9
10 (#) Joint last authors

11
12 **Universidade Federal de Pelotas, Brazil** (Dr. Pedro C Hallal, Prof. Aluísio J D Barros,
13 Prof. Bernardo L Horta, Prof. Mariângela F Silveira, Prof. Odir A Dellagostin, Dr.
14 Fernando P Hartwig, Prof. Ana B Menezes, Prof. Fernando C Barros, Prof. Cesar G
15 Victora), **Fundação Universidade Federal de Ciências de Saúde de Porto Alegre, Brazil**
16 (Prof. Lúcia C Pellanda, Profa Marília A Mesenburg), **Fundação Getúlio Vargas and**
17 **Universidade do Estado do Rio de Janeiro, Brazil** (Prof. Claudio J Struchiner),
18 **Universidade de São Paulo, Brazil and Universidade Federal de São Paulo, Brazil**
19 (Prof. Marcelo N Burattini), **Universidade de Santa Cruz do Sul, Brazil** (Profa. Andréia R
20 M Valim), **Universidade de Ijuí, Brazil** (Profa Evelise M Berlezi), **IMED - Passo Fundo,**
21 **Brazil,** (Prof. Jeovany M Mesa), **Universidade do Vale do Rio dos Sinos, Brazil** (Profa.
22 Maria Letícia R Ikeda), **Universidade de Caxias do Sul, Brazil** (Profa. Marina Mantesso),
23 **Universidade Federal de Santa Maria, Brazil** (Profa. Marinel M Dall'Agnol), **Secretaria**
24 **Municipal de Saúde de Uruguaiana, Brazil** (Raqueli A Bittencourt).

25
26 **Correspondence to:** Pedro C Hallal, Marechal Deodoro 1160 – 96020-220 - Pelotas, RS,
27 Brazil – Phone (fax): +55 53 3284-1300 - Email: prchallal@gmail.com

28
29 **Funding:** This work started through the Data Committee created by the State of Rio
30 Grande do Sul government to fight the COVID-19 pandemics. The tests used in the
31 study have been provided by the Brazilian Ministry of Health. Funding for data
32 collection was provided by UNIMED Porto Alegre, Instituto Cultural Floresta and
33 Instituto Serrapilheira.

34

35 ABSTRACT

36

37 Population based data on COVID-19 are urgently needed for informing policy decisions,
 38 yet few such studies are available anywhere, as most surveys rely on self-selected
 39 volunteers. In the Brazilian State of Rio Grande do Sul (population 11.3 million), we are
 40 carrying out fortnightly household surveys in nine of the largest cities. Multi-stage
 41 probability sampling was used in each city to select 500 households, within which one
 42 resident was randomly chosen for testing. The Wondfo lateral flow rapid test for
 43 detecting antibodies against SARS-CoV-2 has been validated in four different settings,
 44 including our own, with pooled estimates of sensitivity (84.8%, 95% CI 81.4%;87.8%)
 45 and specificity (99.0%, 95% CI 97.8%;99.7%), which are within the acceptable range for
 46 epidemiological studies. In the first wave of the study (April 11-13), 4,188 subjects
 47 were tested, of whom two were positive (0.0477%; 95% confidence interval (CI)
 48 0.0058%;0.1724%). In the second round (Apr 25-27) there were six positive subjects
 49 (0.1333%; 95% CI 0.0489%;0.2900%). We also tested family members of positive index
 50 cases, and nine out of 19 had positive results. Testing of reported COVID-19 cases
 51 according to RT-PCR confirmed that the test was highly sensitive under field
 52 conditions. The epidemic is at an early stage in the State, as the first case was reported
 53 on Feb 28, and by Apr 30, 50 deaths were registered. Strict lockdown measures were
 54 implemented in mid-March, and our results suggest that compliance was high, with full
 55 or near full compliance rates of 79.4% in the first and 71.7% in the second round. As far
 56 as we know, this is the only large population anywhere undergoing regular household
 57 serological surveys for COVID-19. The results show that the epidemic is at an early
 58 phase, and findings from the next rounds will allow us to document time trends and
 59 propose Public Health measures.

INTRODUCTION

Despite calls for population-based data on COVID-19,¹ there have been remarkably few household seroprevalence surveys anywhere, and none in Latin America.² In Rio Grande do Sul, the southernmost state in Brazil (population 11.3 million), the first case of COVID-19 was diagnosed on February 29, 2020. As of April 30, 1,466 confirmed cases (129 per 1,000,000 inhabitants) and 50 deaths had been reported (<http://ti.saude.rs.gov.br/covid19/>). It is important to remark that in the state, as also in Brazil, only persons with moderate to severe symptoms had been tested, using PCR to detect SARS-Cov-2. The state and most municipal governments issued strong social distancing policies in mid-March, including closures of schools, shops and services, except for businesses deemed to be essential.

Other than studies based on convenience samples, such as individuals who volunteered to be tested, supermarket customers, or blood donors, there are few general population sample surveys in the literature. In a national study in Iceland³, one of the three groups of participants was recruited through random sampling of the population, but only about one third of those invited were tested. In this group, 13 of 2283 persons tested positive (0.6%; 95% CI 0.3;0.9) in quantitative real-time polymerase-chain-reaction (qRT-PCR) assays. A national household study in Austria used random sampling to invite households to participate. Of the households contacted, 77% or 2,197 declared their willingness to participate, and 1,541 persons were successfully tested. Assuming two persons per household, those tested correspond to about 30% of the intended sample. The study found a prevalence of 0.33% (95% CI 0.12;0.76%) using qRT-PCR, or 5 individuals out of those tested.⁴ Smaller studies in hot spots for COVID-19 showed prevalence of 14% the German city of Gangelt⁵ and 3% in the Italian village of Vò.⁶

As expected, studies based on volunteers found higher prevalence, as was the case for the first study in Iceland (0.9%)³, the population screening in South Korea (2.1%)⁷ and two studies in California: prevalence of 1.5% in Santa Clara county⁸ and 4.1% in Los Angeles County.

<http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=2328>

Starting on April 11-13, we set out to test the presence of antibodies against SARS-CoV-2 in population-based samples of 500 individuals in each of nine sentinel cities in the state, with a total sample of 4,500. The same methodology was used in a second round in the same cities on April 25-27, and subsequent rounds are planned to take place every two weeks in order to monitor how the pandemic is evolving.

METHODS

The state of Rio Grande do Sul is divided by the National Institute of Geography and Statistics in eight intermediary regions (Figure 1). The main city in each region was selected for the study. In the main metropolitan region, we selected the State Capital, Porto Alegre, and Canoas, the second largest city in the metropolitan area. Populations ranged from 78,915 in Ijuí to 1,409,351 in Porto Alegre (<https://cidades.ibge.gov.br/brasil/rs/panorama>).

Figure 1. Location of the nine sentinel cities.

We used multistage sampling to select 50 census tracts with probability proportionate to size in each sentinel city, and 10 households at random in each tract based on census listings updated in 2019. All household members were listed at the beginning of the visit, and one individual was randomly selected through an app used for data collection. The survey waves took place on April 10-12 and 25-27.

The Statewide sample of 4,500 individuals allows estimating a prevalence levels of 3% and 10% with margins of error of 0.5 and 1.0 percent points, respectively.

122 In the first wave, interviewers had listings of 35 households in each tract. Any refusals
123 at household level led to selection of the next household in the list, and so on until 10
124 households were included. In the second wave, field workers went to the house visited
125 in the first wave, and then selected the tenth household to its right. In case of refusal,
126 the next household to the right side was selected. In the case of acceptance at the
127 household level but the index individual refused to provide a sample, a second
128 member was selected. If this person also refused, the field workers moved on to the
129 next household in the list.

130
131 Prevalence of antibodies was assessed with a rapid test using finger prick blood
132 samples - the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou,
133 China). This test detects immunoglobulins of both IgG and IgM isotypes specific to
134 SARS-CoV-2 antigens in a lateral flow assay. The capture reagent consists of an
135 unspecified viral antigen immobilized at a defined position on a nitrocellulose
136 membrane. Following the introduction of the sample, a solution containing labelled
137 detector anti-immunoglobulin monoclonal antibodies is added. If the test is valid, a
138 control line appears on the kit's window. If this line is not visible, the test is deemed
139 inconclusive, which is very uncommon. A positive result is triggered by binding of the
140 detector antibody to any serum immunoglobulins immobilized on the viral antigen,
141 and is visible as a second colored line. Two drops of blood from a pinprick are sufficient
142 to detect the presence of antibody.

143 Four independent validation studies are available for the rapid test. Its sensitivity and
144 specificity are 86.4% and 99.6% according to the manufacturer, using samples
145 collected from 361 confirmed cases and 235 negative
146 controls(<https://en.wondfo.com.cn/product/wondfo-sars-cov-2-antibody-test-lateral-flow-method-2/>). The tests were purchased in bulk by the Brazilian government, being
147 earmarked for use in population surveys and surveillance programs. An initial
148 validation study was carried out by the National Institute for Quality Control in Health
149 (INCQS, Oswaldo Cruz Foundation, RJ, Brazil) using 18 qRT-PCR positive and 77
150 negative serum samples. The reported sensitivity was 100.0% (95% confidence interval
151 (CI) 81.5;100.0%), while specificity was 98.7% (95% CI 93.0;100.9%). Recently,
152 Whitman and colleagues⁹ evaluated 10 different lateral flow assays using as
153 specimens plasma or serum samples from symptomatic SARSCoV-2 RT-PCR-positive
154 individuals and 108 pre-COVID-19 negative controls. Sensitivity of the Wondfo test was
155 81.5% (95% CI 70.0-90.1%) among 65 patients with a positive RT-PCR 11 or more days
156 before the test, and specificity was 99.1% (95% CI 94.9;100.0%). Of the 10 tests
157 studied, the Wondfo test was one of the two lateral flow tests with the best
158 performance. Lastly, we carried out our own validation study, based on 83 volunteers
159 with a positive qRT-PCR result 10 days or more before the rapid test. This analysis
160 showed a sensitivity of 77.1% (95% CI 66.6;85.6%). We also analysed 100 sera samples
161 collected in 2012 from participants of the 1982 Pelotas (Brazil) Birth Cohort Study¹⁰
162

163 and found 98 negative results, yielding a specificity estimate of 98.0% (95% CI
164 93.0;99.8%). By pooling the results from the four separate validations studies,
165 weighted by sample sizes, sensitivity is estimated at 84.8% (95% CI 81.4%;87.8%) and
166 specificity at 99.0% (95% CI 97.8%;99.7%).

167

168 Participants answered short questionnaires including sociodemographic information
169 (sex, age, schooling and skin color), COVID-19-related symptoms, use of health
170 services, compliance with social distancing measures and use of masks. Field workers
171 used tablets or smartphones to record the full interviews, register all answers, and
172 photograph the test results. All positive or inconclusive tests were read by a second
173 observer, as well as 20% of the negative tests. If the index subject in a household had a
174 positive result, all other family members were invited to be tested.

175

176 Interviewers were tested and found to be negative for the virus, and were provided
177 with individual protection equipment that was discarded after visiting each home.
178 Ethical approval was obtained from the Brazilian's National Ethics Committee (process
179 number 30415520.2.0000.5313), with written informed consent from all participants.
180 Positive cases were reported to the statewide COVID-19 surveillance system. The study
181 protocol was published prior to the first wave of data collection.¹¹ Data will become
182 publicly available upon request from the corresponding author 30 days after publication.

183

184 In the analyses reported in the body of this article, we analyzed the surveys as if they
185 included simple random samples from the population, using the exact binomial
186 method for confidence intervals. We calculated absolute (in percent points) and
187 relative differences between the two survey waves regarding the prevalence of
188 infection. P-values were calculated using Cochran's Q heterogeneity test, implemented
189 as fixed-effects meta-regression, which also yielded confidence intervals for the
190 differences. More complex analyses with allowances for the sampling design,
191 population weights and corrections for the specificity and sensitivity of the rapid test,
192 are included in the web annex. All analyses were performed using R version 3.6.1
193 (<https://www.r-project.org/>). The "metafor" package was used to compare the
194 prevalence between surveys.

195

196 RESULTS

197

198 Out of the planned 4,500 interviews, it was possible to test 4,188 individuals in the first
199 round. The number of tests carried out included 500 in each of five cities (Pelotas,
200 Passo Fundo, Santa Cruz, Caxias), 396 in Porto Alegre, 332 in Canoas, 499 in
201 Uruguaiana and 461 in Santa Maria. In the last three cities, the desired sample size was
202 not completed due to logistic difficulties resulting from the need to complete the
203 survey in a 3-day period. Refusals, requiring the selection of the next household in the
204 census tract listing, ranged from 5.4% in Ijuí to 26.9% in Santa Maria, with a median of
205 17.9% in the nine cities. In the second round, it was possible to obtain 500 interviews
206 in each of the nine cities.

207

208 Table 1 shows the characteristics of individuals who provided blood samples. Both
209 samples were similar in terms of sex, age, skin color and schooling distributions.
210 Although the nine sentinel cities are not representative of the state as a whole, the
211 comparison shows what the samples had higher proportions of women and of older
212 persons than the state as a whole. Young children were particularly underrepresented.
213 Up-to-date information on schooling is not available for the State.

214

215 Of the 4,188 individuals tested in the first round, 10 had inconclusive results and only
216 two (0.0477%; 95% confidence interval (CI) 0.0058%;0.1724%) tested positive, one
217 each in the cities of Pelotas and Uruguaiana. In the second round, there were two
218 inconclusive results and six positive subjects (0.1333%; 95% CI 0.0489%;0.2900%). The
219 absolute prevalence difference between the second and first waves was equal 0.086
220 percent point (95% CI -0.400;0.211; P=0.181), and the ratio was equal to 2.793 (95% CI
221 0.564;13.831, P=0.208).

222

223 Given the small numbers of subjects who tested positive, we focus the presentation on
224 unadjusted results. The web annex provides results from more complex analyses, all of
225 which produced results that are highly comparable to those reported here.

226

227 Regarding social distancing measures, 20.6% of respondents reported leaving home on
228 a daily basis, 58.3% leaving home occasionally for essential activities, and 21.1%
229 staying at home all the time in the first phase, and 28.3%, 53.4% and 18.3%,
230 respectively, in the second phase.

231

232 The households of the eight positive cases in the two phases included other 20
233 residents. Of these, 19 were tested; the rapid test showed nine positive, eight
234 negative, and two inconclusive results. One positive case lived alone. Among the other
235 seven, four had at least another positive individual in their families.

236

Table 1. Sociodemographic characteristics of the two samples in nine cities and of the State population.

	ROUND 1	ROUND 2	STATE POPULATION ^{12,13}
SEX	%	%	%
Male	41.7	40.5	48.7
Female	58.3	59.5	51.3
AGE			
0-9	3.6	2.6	12.3
10-19	5.4	5.1	12.6
20-29	12.2	11.4	15.1
30-39	15.3	16.9	15.1
40-49	15.5	14.6	13.3
50-59	17.9	17.9	12.9
60-69	16.4	17.9	10.2
70-79	9.4	10.2	5.7
80+	4.3	3.4	2.9
SKIN COLOR			
White	76.6	75.9	81.5
Brown	15.8	16.2	13.0
Black	6.5	6.6	5.2
Other	1.1	1.3	0.3
EDUCATION			
Primary or less	37.4	34.1	Not available
Secondary	29.8	31.8	
University or higher	32.8	34.1	

As an additional check on how the rapid test performed under field work conditions, we conducted two separate assessments. The first was during the validation study in Porto Alegre, where 83 RT-PCR positive individuals were tested in the field using the rapid test. As described in the Methods section, 64 of these had positive results with the rapid test. Second, a more limited assessment entailed asking the coordinators of field work in different cities whether they were aware of any RT-PCR positive individuals in their communities. Four persons were identified and tested, all of whom had positive results in the rapid test.

253 DISCUSSION

254

255 This is the first report on repeated population-based surveys for the detection of SARS-
256 CoV-2 antibodies. With two weeks interval we were able to perform antibody tests on
257 representative samples in nine sentinel cities in Rio Grande do Sul State in Southern
258 Brazil.

259

260 Based on reported death rates by April 30, 2020, Rio Grande do Sul is one of the six
261 states, out of 27, with the lowest mortality, of 4 per million, well below Rio de Janeiro
262 (46 per million) or Sao Paulo (49 per million). Amazonas state (92 per million) shows
263 the highest death rates. The national mortality rate is estimated at 26 per million.

264 (<https://covid.saude.gov.br/>)

265

266 Taking our present results at face value, there would be 477 cases per million
267 inhabitants (95% confidence interval 58-1,719 cases) in the first wave, compared to 62
268 reported cases per million, as of April 14. According to the results of the second wave
269 (April 25-27), there would be 1,333 cases per million inhabitants (95% CI 489;2900)
270 compared to 128 reported cases per million as of April 30. Additional estimates, taking
271 into account corrections for the sample design, population weighting and adjustment
272 for sensitivity and specificity, are provided in the web annex.

273

274 Important concerns have been issued about rapid serological tests, but these mostly
275 refer to their use in making clinical decisions,¹⁴ and on issuing “immunity passports”¹⁵
276 for individuals who are assumed to have developed immunity. Both of these
277 circumstances refer to individual-level diagnoses based on rapid tests. Use of rapid
278 tests for population-based estimates, and particularly for monitoring trends over time,
279 is a different issue for which rapid tests with less than perfect sensitivity and specificity
280 may be acceptable. The Wondfo lateral flow test used in our analyses underwent four
281 different validation studies, being able to correctly identify 5 out of every 6 RT-PCR
282 confirmed cases, and 99 out of 100 individuals without SARS-CoV-2 antibodies. Among
283 10 lateral flow tests recently assessed by Whitman and colleagues⁹, it was among the
284 two with the best performance. Our finding of positive results for 10 of 13 family
285 members of the six index individuals who tested positive confirms that the
286 performance of the rapid test was adequate under field conditions.

287

288 The limitations of our analyses include the restriction of the sample to sentinel cities
289 that jointly account for 31% of the state’s population, while smaller towns and rural
290 areas were not included. Second, antibody tests result in many false negatives for
291 recent infections, particularly within the first two weeks since contagion, and thus
292 prevalence reflects levels of infection a week or two prior to the survey, about 15 days
293 after the first case was reported in the state. The non-response rate at household

level, estimated at 17.9%, was low compared to other population-based studies,^{3,4} or to studies based on volunteers. Our samples had fewer children than expected, which was probably due to their reluctance to undergo a finger prick when randomly selected within the household; in these cases, a second person was randomly selected and if that person also refused the household was replaced.

Lastly, our results were at the lower range of the 95% confidence interval for the false positive rate, which in the pooled estimate from four validation studies was estimated at 1.0% (95% CI 0.3%;2.2%). In these studies, specificity was measured in frozen samples. Whitman and colleagues, in their analyses of 10 lateral flow tests, observed *“moderate-to-strong positive bands in several pre-COVID-19 blood donor specimens, some of them positive by multiple assays, suggesting the possibility of non-specific binding of plasma proteins, non-specific antibodies, or cross-reactivity with other viruses.”*⁹ Our results on family clustering show that - out of the seven index cases who lived alone - four had family members who also tested positive. These four individuals are most likely true positives, thus suggesting that up to four of the remaining index cases with positive results, out of 8,689 individuals, might represent false positive results. The test’s specificity would then be equal to 99.95% (95% CI 99.88;99.99%).

Our finding of low prevalence is consistent with an early phase of the pandemic, coupled with high compliance with social distancing measures, as confirmed by our own results. Such a low prevalence level is compatible with other population-based studies: 0.6% in Iceland³ and 0.3% in Austria,⁴ which is close to Northern Italy which was strongly hit by the pandemic. One should note that in both studies about 2/3 of those invited failed to participate, compared to our own non-response rate of 17.9%. Our results are not comparable with those based on self-selected volunteers.

The surveys are being partly funded by the state and national governments of Brazil. Survey results were disseminated, two days after the completion of data collection round, in press briefings with the presence of the state governor, who is making use of the information to guide stay-at-home and other policies. Results from the next rounds of our study – planned for May 8-10 and 22-23 - will allow us to follow the dynamics of the pandemic in the state, especially when social restriction measures are starting to be relaxed in most municipalities.

References

1. Pearce N, Vandenbroucke JP, VanderWeele TJ, Greenland S. Accurate Statistics on COVID-19 Are Essential for Policy Guidance and Decisions. *American journal of public health* 2020: e1-e3.
2. Barreto ML, Barros AJD, Carvalho MS, et al. [What is urgent and necessary to inform policies to deal with the COVID-19 pandemic in Brazil?]. *Rev Bras Epidemiol* 2020; **23**: e200032.
3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *The New England journal of medicine* 2020.
4. Institute for Social Research and Consulting Ogris & Hofinger GmbH (SORA). COVID-19 Prevalence, 2020.
5. Regalado A. Blood tests show 14% of people are now immune to covid-19 in one town in Germany. 2020. <https://www.technologyreview.com/2020/04/09/999015/blood-tests-show-15-of-people-are-now-immune-to-covid-19-in-one-town-in-germany/> (accessed April 27, 2020).
6. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. *BMJ* 2020; **368**: m1165.
7. Ministry of Health and Welfare (South Korea). Coronavirus disease 19, Republic of South Korea. 2020. <http://ncov.mohw.go.kr/en>.
8. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv* 2020: 2020.04.14.20062463.
9. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2 serological assays. (*unpublished*) 2020.
10. Horta BL, Gigante DP, Goncalves H, et al. Cohort profile update: the 1982 Pelotas (Brazil) Birth Cohort Study. *International journal of epidemiology* 2015; **44**(2): 441-e.
11. Hallal P, Horta B, Barros A, et al. Evolução da prevalência de infecção por COVID-19 no Rio Grande do Sul: inquéritos sorológicos seriados. *Cien Saude Colet* 2020.
12. Instituto Brasileiro de Geografia e Estatística. Pesquisa nacional por amostra de domicílios : síntese de indicadores 2015. Rio de Janeiro: IBGE, 2016.
13. Instituto Brasileiro de Geografia e Estatística. Projeções da População. 2019. [HTTPS://WWW.IBGE.GOV.BR/ESTATISTICAS/SOCIAIS/POPULACAO/9109-PROJECAO-DA-POPULACAO.HTML?=&T=RESULTADOS](https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-PROJECAO-DA-POPULACAO.HTML?=&T=RESULTADOS) (accessed April 30, 2020).
14. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. 2020. <https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19> (accessed April 30, 2020).
15. World Health Organization. "Immunity passports" in the context of COVID-19. 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19> (accessed April 30, 2020).